U.S. Food and Drug Administration Issues Complete Response Letter for Lebrikizumab Based on Inspection Findings at Third-Party Manufacturer | Eli Lilly and Company - Investors | Eli Lilly and Company
investor.lilly.comSubmitted by lillycom9342 in business
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders